Alzheimer's disease in Down syndrome: neurobiology and risk
- PMID: 17910085
- DOI: 10.1002/mrdd.20163
Alzheimer's disease in Down syndrome: neurobiology and risk
Abstract
Down syndrome (DS) is characterized by increased mortality rates, both during early and later stages of life, and age-specific mortality risk remains higher in adults with DS compared with the overall population of people with mental retardation and with typically developing populations. Causes of increased mortality rates early in life are primarily due to the increased incidence of congenital heart disease and leukemia, while causes of higher mortality rates later in life may be due to a number of factors, two of which are an increased risk for Alzheimer's disease (AD) and an apparent tendency toward premature aging. In this article, we describe the increase in lifespan for people with DS that has occurred over the past 100 years, as well as advances in the understanding of the occurrence of AD in adults with DS. Aspects of the neurobiology of AD, including the role of amyloid, oxidative stress, Cu/ZN dismutase (SOD-1), as well as advances in neuroimaging are presented. The function of risk factors in the observed heterogeneity in the expression of AD dementia in adults with DS, as well as the need for sensitive and specific biomarkers of the clinical and pathological progressing of AD in adults with DS is considered.
2007 Wiley-Liss, Inc.
Similar articles
-
Atypical aging in Down syndrome.Dev Disabil Res Rev. 2013;18(1):51-67. doi: 10.1002/ddrr.1128. Dev Disabil Res Rev. 2013. PMID: 23949829 Review.
-
Down syndrome and Alzheimer's disease: a link between development and aging.Ment Retard Dev Disabil Res Rev. 2001;7(3):172-8. doi: 10.1002/mrdd.1025. Ment Retard Dev Disabil Res Rev. 2001. PMID: 11553933 Review.
-
Beta-amyloid, oxidative stress and down syndrome.Curr Alzheimer Res. 2006 Dec;3(5):521-8. doi: 10.2174/156720506779025305. Curr Alzheimer Res. 2006. PMID: 17168651 Review.
-
Red cell superoxide dismutase, glutathione peroxidase and catalase in Down syndrome patients with and without manifestations of Alzheimer disease.Am J Med Genet. 1990 Apr;35(4):459-67. doi: 10.1002/ajmg.1320350403. Am J Med Genet. 1990. PMID: 2139757
-
Superoxide dismutase SOD1, encoded on chromosome 21, but not SOD2 is overexpressed in brains of patients with Down syndrome.J Investig Med. 2001 Jan;49(1):41-6. doi: 10.2310/6650.2001.34089. J Investig Med. 2001. PMID: 11217146
Cited by
-
Distinct neuroanatomical and neuropsychological features of Down syndrome compared to related neurodevelopmental disorders: a systematic review.Front Neurosci. 2023 Aug 3;17:1225228. doi: 10.3389/fnins.2023.1225228. eCollection 2023. Front Neurosci. 2023. PMID: 37600012 Free PMC article.
-
Correlating MRI-based brain volumetry and cognitive assessment in people with Down syndrome.Brain Behav. 2023 Oct;13(10):e3186. doi: 10.1002/brb3.3186. Epub 2023 Jul 26. Brain Behav. 2023. PMID: 37496380 Free PMC article.
-
Healthcare and Behavior Changes for Adults With Down Syndrome 1-Year Into COVID-19.Am J Intellect Dev Disabil. 2023 Jul 1;128(4):273-281. doi: 10.1352/1944-7558-128.4.273. Am J Intellect Dev Disabil. 2023. PMID: 37470258
-
Modeling Alzheimer's disease related phenotypes in the Ts65Dn mouse: impact of age on Aβ, Tau, pTau, NfL, and behavior.Front Neurosci. 2023 Jun 28;17:1202208. doi: 10.3389/fnins.2023.1202208. eCollection 2023. Front Neurosci. 2023. PMID: 37449271 Free PMC article.
-
Cognitive outcome measures for tracking Alzheimer's disease in Down syndrome.Int Rev Res Dev Disabil. 2022;62:227-263. doi: 10.1016/bs.irrdd.2022.05.006. Epub 2022 Jul 21. Int Rev Res Dev Disabil. 2022. PMID: 37396708 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
